Minesapride

TargetMol
Product Code: TAR-T28043L
Supplier: TargetMol
CodeSizePrice
TAR-T28043L-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-5mg5mg£416.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-1mL1 mL * 10 mM (in DMSO)£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-10mg10mg£581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-50mg50mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-100mg100mg£1,540.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28043L-500mg500mg£3,026.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Minesapride, a novel 5-hydroxytryptamine 4 (5-HT4) receptor partial agonist, is a potential gastrointestinal prokinetic agent for the treatment of irritable bowel syndrome with constipation.
CAS:
1184662-54-1
Molecular Weight:
453.54
Pathway:
Neuroscience|GPCR/G Protein
Purity:
0.9901
SMILES:
N(C1=C2C=3C(NC2=NC(CC4=CC=CC=C4)=N1)=CC(=CC3)C=5N=NN(C)N5)[C@H]6CC[C@H](N)CC6
Target:
5-HT Receptor

References

Fukudo S, et al. Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2021;19(3):538-546.e8. Hamatani T, et al. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. Aliment Pharmacol Ther. 2020;52(3):430-441. Hamatani T, et al. Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT receptor partial agonist, in healthy elderly and young subjects. Drug Metab Pharmacokinet. 2020;35(6):563-570.